Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists induce mild oxygen drop to mimic Alzheimer's symptoms in healthy brains

NCT ID NCT02891343

Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether lowering oxygen levels (hypoxia) can temporarily cause thinking problems similar to Alzheimer's disease in healthy volunteers. The goal was to create a safe, reversible test to help researchers evaluate new Alzheimer's drugs more quickly. Only 6 healthy, right-handed, non-smoking adults participated before the study was stopped early.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

6 people

The number who actually took part.

Started

Nov 2015

Finished

Dec 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 30 years

Sex

Male participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Good health on the basis of the medical interview, physical examination and standard biology parameters. * Right-Handed * Non-smoker * No cardiac nor pulmonary pathologies * No use of chronic treatment or psychotropic drugs or substances * BMI inferior to 25 Kg/m2 * French speaker and able to understand the test instructions * Informed consent form signed Exclusion Criteria: 1. Subject with history or current brain disease (severe brain trauma, transient ischemic attack, stroke, epilepsy, cerebral tumor…) or retinal pathologies (including familial DMLA) 2. Subject with history of Acute Mountain Sickness, High Altitude Cerebral Edema or High Altitude Pulmonary Edema 3. Subject with other major medical or surgical history including coronaropathy and pulmonary arterial hypertension 4. Subject with current chronic disease 5. Subject with vascular or metabolic risk factor 6. Subject with history of or current mental disease or addiction (MINI) 7. Subject with significant abnormality on biology 8. Subject with significant abnormality on ECG 9. Subject with significant abnormality on MRI 10. Subject with significant abnormality of electrical activities on EEG 11. Subject with family history of young onset dementia 12. Subject with family history of cardiac or pulmonary pathologies 13. Subject with family history of chronic or severe neurological or mental disease (first degree relatives) 14. Subject with claustrophobia or contraindication to MRI 15. Subject under guardianship 16. Subject not covered by Social Security 17. Subject participating in another clinical trial 18. Subject with anxiety (STAI-Trait Score T\> 51) or neuroticism personality (EPI Score N ≥13) 19. Subject bearded or refusing to shave

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alteration of cognitive function are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hypoxia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alteration of cognitive function Hypoxia

Contacts and locations

Locations

  • Centre d'Investigation Clinique, CHRU

    Lille, France

  • Centre d'investigation Clinique

    Marseille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.